Structure and function of plasminogen activator inhibitor-2.
International Journal of Oncology
|April 30, 2011
Summary
Plasminogen activator inhibitor-2 (PAI-2) regulates intracellular pathways and inhibits apoptosis. Its unique CD-domain interacts with cytosolic proteins, potentially influencing cell survival signaling.
Area of Science:
- Molecular biology
- Cellular biology
- Biochemistry
Background:
- Serine proteinase inhibitors (serpins) regulate extracellular proteolysis.
- Intracellular ovalbumine-like serpins, including PAI-2, modulate intracellular pathways.
- PAI-2 is implicated in apoptosis and inflammation regulation.
Purpose of the Study:
- To review the molecular structure-function relationships of PAI-2.
- To elucidate the intracellular functions of PAI-2, particularly its role in apoptosis.
- To identify the protein targets and signaling pathways involved in PAI-2's antiapoptotic activity.
Main Methods:
- Literature review of PAI-2 structure and function.
- Analysis of PAI-2's role in apoptosis in cell lines.
- Investigation of PAI-2 interactions with cytosolic proteins, including annexins.
Main Results:
- PAI-2 inhibits apoptosis induced by tumor necrosis factor and viruses.
- PAI-2 undergoes proteolytic modification during myeloid apoptosis.
- The CD-domain and reactive site of PAI-2 are crucial for its antiapoptotic function.
- The CD-domain mediates interactions with cytosolic proteins like annexins.
Conclusions:
- PAI-2 possesses significant intracellular antiapoptotic functions.
- The unique CD-domain of PAI-2 is essential for its antiapoptotic activity and interactions with cytosolic proteins.
- PAI-2-interacting proteins may be key components of cell survival signaling pathways.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:09Cytoskeletal Linker Proteins - Plakins
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...